Oka Aiko, Yamashita Tamami, Kanai Kengo, Yuta Atsushi, Ogawa Yukiko, Takahara Eriko, Shiratsuchi Hideki, Terada Akihiko, Tsunoda Takatsugu, Masuda Takeshi, Masuno Satoru, Kanai Kenichi, Nagakura Hitoshi, Tokuda Reiko, Arao Harumi, Bamba Hitoshi, Yasuda Shigenobu, Mimura Hideya, Nakazato Mahoko, Nakazato Hidehisa, Houya Noriyuki, Tsuzuki Hideaki, Tokuriki Masaharu, Sakaida Mayuko, Amesara Ryo, Ohkawa Chikahisa, Hama Takemitsu, Ikeda Hiroki, Fukushima Hisaki, Niitsu Sumiko, Sakaguchi Hirofumi, Iba Norihito, Kumanomidou Hiroshi, Hyo Yoshiyuki, Takagi Ryo, Koike Takashi, Yamada Marie, Okano Mitsuhiro
Department of Otorhinolaryngology, International University of Health and Welfare School of Medicine, Chiba, Japan.
Faculty of Medicine, International University of Health and Welfare School of Medicine, Chiba, Japan.
J Allergy Clin Immunol Glob. 2025 Mar 22;4(3):100463. doi: 10.1016/j.jacig.2025.100463. eCollection 2025 Aug.
It remains unclear whether allergen immunotherapy with Japanese cedar pollen extract is effective for Japanese cypress pollinosis in real-world settings.
We sought to investigate the Japan-wide prevalence of cypress pollinosis, the efficacy of cedar sublingual immunotherapy (SLIT) on cypress pollinosis, the role of serum-specific IgE levels in pollinosis, and patients' interest in the development of cypress SLIT.
A cross-sectional, multicenter study using self-administered questionnaires was conducted in regions of Japan where cedar and cypress pollen dispersals are prevalent. This study included patients aged 5 to 69 years who received cedar SLIT in 2023.
Of 2597 participants analyzed, 84.5% experienced pollinosis symptoms during the cypress season before receiving cedar SLIT. Among these patients, 40.2% felt that cedar SLIT was less effective during the cypress season than during the cedar season. The longer the patients received cedar SLIT, the greater the inefficacy perceived during the cypress versus the cedar season. In the symptomatic patients, serum IgE levels were significantly higher for cedar and cypress as compared with those observed in subjects without symptoms during the cypress season. No significant differences were reported in IgE levels for cedar and cypress between patients reporting either high or lower efficacy for the cedar SLIT during cypress season. Interest in cypress SLIT was seen in 78.4% of these patients.
Although there is a bias based on regional distribution, cedar SLIT has induced a limited efficacy on cypress pollinosis in real-world settings, suggesting a need for the development of cypress SLIT.
在现实环境中,日本雪松花粉提取物的变应原免疫疗法对日本扁柏花粉症是否有效仍不清楚。
我们试图调查全日本扁柏花粉症的患病率、雪松舌下免疫疗法(SLIT)对扁柏花粉症的疗效、血清特异性IgE水平在花粉症中的作用以及患者对开发扁柏SLIT的兴趣。
在日本雪松和扁柏花粉传播普遍的地区,采用自行填写问卷的方式进行了一项横断面、多中心研究。本研究纳入了2023年接受雪松SLIT治疗的5至69岁患者。
在分析的2597名参与者中,84.5%在接受雪松SLIT治疗前的扁柏季节出现了花粉症症状。在这些患者中,40.2%的人认为雪松SLIT在扁柏季节的效果不如在雪松季节。患者接受雪松SLIT的时间越长,与雪松季节相比,在扁柏季节感觉到的无效性就越大。在有症状的患者中,与在扁柏季节无症状的受试者相比,雪松和扁柏的血清IgE水平显著更高。在扁柏季节报告雪松SLIT疗效高或低的患者之间,雪松和扁柏的IgE水平没有显著差异。78.4%的这些患者对扁柏SLIT表现出兴趣。
尽管存在基于区域分布的偏差,但在现实环境中,雪松SLIT对扁柏花粉症的疗效有限,这表明需要开发扁柏SLIT。